Home > Resources > Whitepapers > Nasal Drug Delivery Devices and Pain Management Systems

Nasal Drug Delivery Devices and Pain Management Systems

the nasally administered systemic drugs market has an increasing generics sector, is placing greater emphasis on patient compliance and convenience, and is benefitting from an increasingly ageing population.In contrast, severe pressure on health care costs is negatively affecting the market. The Nasal route is beneficial due to its rapid onset of action, it is non-invasive, has good bio-availability, and patients can self-medica

Spotlight

ITH Pharma

ITH Pharma is a new pharmaceutical company committed to the research and development of aseptic preparations and to providing an unrivalled customer service. ITH Pharma specialises in the provision of of aseptic compounding services for all therapy areas - particularly Parenteral Nutrition, Chemotherapy and CIVAS. The company was launched in October 2008 by the founding members of Intra-Tech Healthcare, so although we're new, we are experienced and have the understanding of what you require from a supplier.

OTHER WHITEPAPERS

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

High Pressure Homogenizer for Nano-formulation

whitePaper | December 16, 2022

NanoGenizer, a lab-scale microfluidic high pressure homogenizer, utilizes interaction high-pressure microfluidic jet technology, and it is equipped with highly modular power and processing units.

Why Deck 7

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

Pharma R&D Annual Review 2023

whitePaper | April 20, 2023

Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Nasal Drug Delivery Devices and Pain Management Systems